ZOLINDA 10/MG TAB 30/TAB

Indications

Approved Uses

Schizophrenia; Bipolar I disorder-acute manic/mixed episodes (monotherapy or adjunct to lithium/valproate) and maintenance; Adjunctive treatment of Major Depressive Disorder; Irritability associated with autistic disorder; Tourette’s disorder.

Off-Label Uses

Examples of off-label uses: augmentation in OCD; PTSD; anxiety disorders; behavioral symptoms/agitation in dementia (generally discouraged due to boxed warning/risks); other augmentation strategies in refractory mood disorders.

Dosage & Administration

Dosing by Condition

Schizophrenia (adults): start 10-15 mg once daily; usual 10-15 mg/day; max 30 mg/day. Bipolar I acute mania/mixed (adults): start 15 mg once daily (10-15 mg/day if adjunct); max 30 mg/day. Adjunctive MDD (adults): start 2-5 mg/day; target 5-10 mg/day; max 15 mg/day. Pediatric dosing exists for schizophrenia (13-17), bipolar mania (10-17), autism irritability (6-17), and Tourette’s (6-18) per product labeling in many jurisdictions.

Initial Dose

10-15 mg once daily for schizophrenia; 15 mg once daily for bipolar mania

Maintenance Dose

10-30 mg once daily depending on indication and response

Maximum Dose

30 mg/day.

Children's Dosage

Approved for schizophrenia (13-17 years), bipolar I disorder (10-17 years), irritability with autistic disorder (6-17 years), and Tourette's disorder (6-18 years). Dosing is typically initiated at 2 mg/day and titrated upwards.

Dose Adjustment Notes

Reduce aripiprazole dose by 50% with strong CYP2D6 inhibitors or strong CYP3A4 inhibitors; if both strong CYP2D6 and strong CYP3A4 inhibitors are used together, reduce to 25% of usual dose; with strong CYP3A4 inducers, increase dose (often double) over 1-2 weeks and reduce back when the inducer is stopped; no adjustment is generally required for renal impairment or mild-moderate hepatic impairment.

How to Take

Swallow tablet whole with water; may be taken with or without food; take once daily and preferably at the same time each day.

Side Effects

Common Side Effects

Nausea, vomiting, constipation, headache, dizziness, akathisia, insomnia, somnolence, restlessness, blurred vision, weight gain, anxiety, fatigue

Safety & Warnings

Contraindications

Known hypersensitivity to aripiprazole or any component of the formulation.

Warnings & Precautions

Key warnings/precautions: not approved for dementia-related psychosis and increased mortality in elderly with dementia-related psychosis; monitor for suicidality/behavioral changes; watch for NMS and tardive dyskinesia; monitor weight, glucose and lipids; caution in cardiovascular/cerebrovascular disease and hypotension risk; seizure risk; monitor CBC if history of low WBC; monitor for impulse-control disorders and dysphagia/aspiration risk.

Age Restriction

Approved for certain pediatric indications from age 6 years; not approved for children <6 years.

Driving Warning

May Cause Drowsiness

Drug Interactions

Drug Interactions

Major interactions: strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) increase aripiprazole exposure-dose reduction typically required; strong CYP3A4 inducers (e.g., carbamazepine, rifampin) decrease exposure-dose increase may be required; additive effects with CNS depressants and antihypertensives (hypotension).

Interaction Severity

MAJOR: Strong CYP3A4 inducers (e.g., carbamazepine, rifampin) and strong CYP3A4 inhibitors (e.g., ketoconazole/itraconazole/clarithromycin) and strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) due to large exposure changes requiring dose adjustment. MODERATE: Additive CNS depression with alcohol/sedatives; enhanced hypotension with antihypertensives.

Food Interaction

No restriction.

Special Populations

Pregnancy

Not assigned a pregnancy category (Risk Summary: Neonates exposed to antipsychotic drugs during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms

Children

Approved for schizophrenia (13-17 years), bipolar I disorder (10-17 years), irritability with autistic disorder (6-17 years), and Tourette's disorder (6-18 years). Dosing is typically initiated at 2 mg/day and titrated upwards.

Elderly

Start at lower dose, titrate slowly, and monitor for side effects, particularly orthostatic hypotension. Not approved for dementia-related psychosis due to increased risk of death.

Kidney Impairment

No adjustment needed

Liver Impairment

No dosage adjustment is generally required in hepatic impairment, including severe hepatic impairment; use clinical caution and monitor.

Storage & Patient Advice

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule; do not double doses.

Stopping the Medicine

Do not stop abruptly - taper gradually under medical supervision to avoid withdrawal symptoms and relapse

Overdose

Overdose: commonly somnolence, vomiting, tremor, tachycardia; may include hypotension, CNS depression, and rare serious events-management is supportive with airway/ventilation, cardiovascular monitoring, and consideration of activated charcoal if early; no specific antidote.

Patient Counseling

Take once daily with or without food, ideally at the same time each day; do not stop abruptly without prescriber advice; avoid alcohol and use caution with driving until effects are known; rise slowly to reduce dizziness; report new/worsening mood or suicidal thoughts, abnormal involuntary movements, symptoms of high blood sugar, fever/rigidity/confusion (possible NMS), and any new impulse-control urges (e.g., gambling, spending, hypersexuality); keep follow-up appointments for metabolic and movement monitoring and review all concomitant medicines for interactions.

Monitoring Requirements

Baseline and periodic: weight/BMI (± waist circumference), blood pressure, fasting glucose or HbA1c, lipid profile; assess for extrapyramidal symptoms/tardive dyskinesia (e.g., AIMS), akathisia, and symptoms of NMS; consider CBC in patients with prior low WBC/neutropenia; monitor mental status/suicidality and impulse-control symptoms.

Pharmacology

Mechanism of Action

Partial agonist at dopamine D2 (and D3) and serotonin 5‑HT1A receptors, and antagonist at serotonin 5‑HT2A receptors.

Onset of Action

Initial effects may be noticed within several days to 2 weeks; full therapeutic response often takes 4-6 weeks.

Duration of Effect

Approximately 24 hours per dose (once-daily dosing) for receptor occupancy/plasma exposure; clinical symptom improvement typically persists for days to weeks with continued therapy and may take 4-6 weeks to reach full therapeutic effect.

Half-Life

Aripiprazole: approximately 75 hours. Active metabolite (dehydro-aripiprazole): approximately 94 hours.

Metabolism

Extensive hepatic metabolism mainly via CYP2D6 and CYP3A4 (dehydrogenation, hydroxylation, N-dealkylation) to an active metabolite, dehydro-aripiprazole.

Excretion

Primarily excreted as metabolites: ~55% in feces and ~25% in urine; <1% excreted unchanged in urine.

Product Information

Available Dosage Forms

Tablet, oral solution, orally disintegrating tablet, intramuscular injection, extended-release intramuscular injectable suspension

Composition per Dose

Each tablet: 10 mg aripiprazole

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Psych Class

Antipsychotic-Atypical

Controlled Substance

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.